After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
After more discontinuations, a new deal brings in fresh blood.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
The CD70-targeting CTX131 heads for the scrapheap.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
